|
|
Upfront Briefing
Erasca showed four responders and raised $550M. Agenus killed a Phase 3 it started in April, announced a $340M placement, and doubled. Q32 rose 60% on 33 patients. Somewhere in there is a market signal, and it is not subtlety.
The FDA had the quieter, more consequential day: Eisai's subcutaneous Leqembi starting dose cleared six weeks ahead of its PDUFA, and the agency finalised its psychedelics guidance while penning in a September hearing. Psilocybin now has a roadmap. Pancreatic cancer, as ever, has a maybe.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,515.3 |
(0.8%) |
9.6% |
| Nasdaq 100 |
29,264.1 |
(1.9%) |
16.1% |
| Russell 2000 |
2,953.2 |
(0.8%) |
17.7% |
| Healthcare (XLV) |
161.4 |
0.4% |
4.7% |
| Biotech (XBI) |
155.3 |
(2.3%) |
27.8% |
| Nasdaq Biotech (NBI) |
6,546.6 |
(1.5%) |
14.7% |
| Clinical Trials (BBC) |
51.3 |
(3.4%) |
36.4% |
|
- Biotech underperformed the tape even as single names ripped — Agenus doubled, Q32 rose 60%, Erasca priced $550M — with XBI and NBI lagging as index-level risk came off and Erasca's supply hit a soft session.
- The broader selloff was geopolitical: Trump reinstated a blockade on Iranian shipping through the Strait of Hormuz with a 20% cargo levy, sending crude up roughly 9% and dragging semis lower — SK Hynix fell 9%, Micron 4%, Intel 6% — with the Nasdaq Composite off 1.55%.
- Market data: U.S. cash close Monday, 13 July 2026.
The Big 3
|
1
|
FDA clears Leqembi Iqlik SC initiation in early Alzheimer's
|
-
Days after Eisai showed AAIC that subcutaneous lecanemab matches IV, FDA approved LEQEMBI IQLIK as a once-weekly SC initiation dose in early Alzheimer's — 500 mg as two 250 mg autoinjector shots, ~15 seconds each — roughly six weeks ahead of its 24 August PDUFA, with U.S. launch planned for late August.
- Why it matters: Eisai and Biogen now own the only anti-amyloid regimen that never requires an infusion chair — SC from day one through maintenance, with the 360 mg weekly maintenance dose already cleared. That removes the infusion-centre bottleneck that has throttled Leqembi's launch since 2023 and is the sharpest available wedge against Lilly's Kisunla, which still starts IV. An approval six weeks inside an extended PDUFA says the file was clean. The catch: convenience does not fix the diagnostic funnel, the APOE4 genotyping step or the boxed ARIA warning, and specialty-pharmacy distribution shifts the reimbursement fight from Part B to Part D. BioArctic (BIOA B) is the third listed beneficiary and the one with the most torque.
- Source: PR
- More: ADDF
|
|
2
|
Erasca turns a seven-patient KRAS signal into $550M
|
- ERAS-0015, an oral pan-RAS molecular glue, posted a 57% unconfirmed ORR at eight weeks in 2L+ KRAS G12X pancreatic cancer (n=7, 32 mg QD recommended expansion dose, 25 May cutoff); hours later Erasca priced an upsized 31,428,572-share offering at $17.50 for $550.0M gross, plus a 30-day option on 4,714,285 more.
- Why it matters: Read the denominator. Fifty-seven percent of seven patients is four responders, unconfirmed, in a franchise Erasca licensed from China's Joyo Pharmatech for $150M — and the raise came at $17.50 against a stock that has run 399% year-to-date to a ~$5.6B cap. The setup is a direct collision with Revolution Medicines, whose daraxonrasib carries Phase 3 RASolute 302 data and ~13.2-month median OS in the same indication; RevMed sent Erasca a legal threat over its best-in-class claims in April, and that April dataset included a patient death. Erasca is now funded through Phase 3 starts in 2027 with no confirmatory data until H1 2027 — a long time to hold a story stock on four responders.
-
Source:
PR
-
More:
PR;
STAT (April data)
|
| 3 | Agenus kills a Phase 3, raises $340M, doubles |
-
Agenus scrapped BATTMAN - the 830-patient Phase 3 of botensilimab plus balstilimab in refractory MSS metastatic colorectal cancer it only launched in April - to redirect BOT+BAL into ROBBIN, a registrational Phase 3 in neoadjuvant high-risk stage II/III MSS colon cancer, alongside an oversubscribed private placement of up to $340M ($85M upfront, up to $255M on warrant exercise). AGEN closed up roughly 115%.
-
Why it matters:
A biotech abandoning a Phase 3 twelve weeks after enrolling the first patient usually means the trial was uninvestable, not the drug - and the market read the pivot, not the abandonment. Refractory mCRC is where checkpoint inhibitors go to die; moving to intact tumours in the neoadjuvant setting is where BOT+BAL's 42% two-year OS and ~21-month median OS in the Phase 1b actually have a shot at translating, against a US population Agenus sizes at 38,000 patients a year and a $7B opportunity with nothing curative approved in two decades. The financing funds through interim pathologic response and both EFS analyses, out to 2031 on full exercise - Agenus has bought itself out of the going-concern conversation. The risks are undiminished: warrant-heavy structure means the $340M is mostly conditional, a neoadjuvant CTLA-4 combo in a cold tumour is still a bet on a mechanism that has never worked there, and a company that walks away from a Phase 3 in ninety days has just told you how it will treat the next one.
-
Source:
Fierce Biotech
-
More:
SEC 8-K
|
Everything Else that broke
- FDA finalized its psychedelics clinical-trial guidance and set a 14 September public hearing on therapeutic use, with Jefferies calling the pair a de-risking event for Compass Pathways (CMPS) and atai/Beckley (ATAI). — Endpoints
- FDA proposed a simpler factory-registration rule for drugmakers serving the U.S. market. — Federal Register
- Freenome reported improved colorectal cancer blood test data versus earlier results. — BioPharma Dive
- Q32 Bio shares rose about 60% after bempikibart, an anti-IL-7R antibody licensed from BMS, hit a 30.3% SALT-20 response at 36 weeks in Part B of Signal-AA (n=33, severe/very severe alopecia areata; 40% in the 25-patient mITT set), with no treatment-related grade 3+ events and a registration-directed program planned for H1 2027. — Fierce Biotech
- China Medical System (867.HK) returned to Insilico Medicine (03696.HK) for a second pact in five months - RMB 1.2B ($177M) in milestones plus royalties on a PandaOmics-nominated CNS target with an undisclosed "mass-market" indication. — Fierce Biotech
- Merck KGaA imposed an in-office requirement on its US research team that could result in up to 70 layoffs. — Fierce Biotech
- Ipsen's Iqirvo (elafibranor) hit statistically significant ALP normalization in a Phase IIIb study in primary biliary cholangitis. — Ipsen
- Digital health startups raised $7.4B in 1H 2026, up $1.0B year over year. — Rock Health
- Roche's Huntington's setback sharpened focus on Wave Life Sciences' selective ASO WVE-003. — BioSpace
- Roche launched a CE-marked cobas HDV test for its 5800, 6800 and 8800 systems. — PR
- An Alzheimer's biomarker blood test improved diagnostic accuracy in routine-care physicians. — PR
- CMS granted Embolx a new HCPCS Level II G-code effective July 1, 2026. — PR
- A dementia risk-reduction study replicated prior promising outcomes in culturally tailored programs. — STAT
- A Cayman court said Apple Tree's general partner should lose control of a venture fund. — Endpoints
- MBX Biosciences named Steve Hoerter CEO and John Smither CFO, effective immediately. — PR
- Tarsus changed commercial leadership and named Neera Clase interim chief commercial officer. — PR
- Eupraxia updated its leadership team and operating structure for its next development phase. — PR
- Astrana Health added Daniel Rothman and Vishal Gupta to senior leadership. — PR
- Lakefront director Paulo Fontoura resigned after becoming Sanofi's global head of R&D. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Insilico Medicine / China Medical System - AI-empowered CNS discovery collaboration; RMB 1.2B ($177M) in milestones plus royalties to Insilico. — Fierce Biotech
VC / Private Financings
- Agenus priced an oversubscribed private placement of up to $340M - $85M upfront plus up to $255M on warrant exercise - funding the registrational ROBBIN Phase 3 of BOT+BAL in MSS colon cancer through year-end 2031 on full exercise. — SEC
- Drug Farm closed a $55M Series D backed by Shanghai Pudong Leading Area Investment Center, BioVeda China Fund, Tukar Capital and Detong Capital, funding Phase 3 DF-003 in ROSAH syndrome and Phase 2 DF-006 in HBV/HCC. — Fierce Biotech
IPOs / Follow-Ons
- Erasca priced a $550.0M upsized follow-on at $17.50 a share, plus a 30-day option for 4,714,285 additional shares. — PR
- Agenus priced an oversubscribed private placement of up to $340M — $85M upfront plus up to $255M on warrant exercise — funding the registrational ROBBIN Phase 3 of BOT+BAL in MSS colon cancer through year-end 2031 on full exercise. — SEC
Academic Corner - A phase 1 Nature Medicine paper reported acceptable safety and encouraging preliminary efficacy for DYP688, an anti-PMEL ADC carrying a Gq/11 inhibitor payload, in GNAQ/GNA11-mutant melanomas. — Nature Medicine
- Nature RDD outlined how simulation-guided trial design could accelerate development, especially in adaptive and master-protocol settings. — Nature RDD
|
That's all for today. Four responders, half a billion dollars — biotech's math is back. — BioBucks Team
|
|
|
